Breaking News
About Telix Pharmaceuticals
Related Story
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
May 8 2023
Telix Pharmaceuticals today announces that it has entered into an agreement with Bayer AG (Bayer) […]
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
March 14 2023
Telix Pharmaceuticals today announces additional positive results from its completed pivotal Phase III ZIRCON study […]
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
March 9 2023
Telix Pharmaceuticals today announces presentations from the Company’s carbonic anhydrase IX (CAIX) targeting kidney and […]
Telix Pharmaceuticals ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU Along with Theranostic Pipeline Advances
December 22 2022
Telix Pharmaceuticals has announced that the completed pivotal Phase III ZIRCON study of TLX250-CDx in […]
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
December 14 2022
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) […]
Telix Announces Executive Leadership Appointments
December 5 2022
Telix Pharmaceuticals has announced several key executive leadership appointments and promotions, reflecting the increased commercial […]
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
November 22 2022
Telix Pharmaceuticals has announced that a first patient has been dosed in a Phase II […]
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
September 29 2022
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products […]
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
June 13 2022
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) […]